2000
PSA based review of adjuvant and salvage radiation therapy vs. observation in postoperative prostate cancer patients
Peschel R, Robnett T, Hesse D, King C, Ennis R, Schiff P, Wilson L. PSA based review of adjuvant and salvage radiation therapy vs. observation in postoperative prostate cancer patients. International Journal Of Cancer 2000, 90: 29-36. PMID: 10725855, DOI: 10.1002/(sici)1097-0215(20000220)90:1<29::aid-ijc4>3.0.co;2-5.Peer-Reviewed Original ResearchConceptsPostoperative radiation therapyBNED survival ratesAdjuvant radiation therapyHigh-risk patientsSalvage radiation therapyPostoperative prostate cancer patientsProstate cancer patientsRadiation therapySurvival ratePSA levelsBiochemical failureCancer patientsBiochemical disease-free survival ratesHigh-risk surgery patientsDisease-free survival ratesAdjuvant radiation groupPreoperative PSA levelSeminal vesicle involvementEarly prostate cancerLife table methodAdjuvant settingSalvage radiationClinical recurrenceSurgery patientsClinical factors
1999
Total skin electron radiation for patients with erythrodermic cutaneous T‐cell lymphoma (mycosis fungoides and the Sézary syndrome)
Jones G, Rosenthal D, Wilson L. Total skin electron radiation for patients with erythrodermic cutaneous T‐cell lymphoma (mycosis fungoides and the Sézary syndrome). Cancer 1999, 85: 1985-1995. PMID: 10223240, DOI: 10.1002/(sici)1097-0142(19990501)85:9<1985::aid-cncr16>3.0.co;2-o.Peer-Reviewed Original ResearchConceptsErythrodermic mycosis fungoidesBlood involvementMycosis fungoidesCutaneous remissionSpecific survivalStage IIIErythrodermic cutaneous T-cell lymphomaTotal skin electron beam radiationMedian cause-specific survivalCutaneous T-cell lymphomaMedian overall survivalStage IVB diseaseCause-specific survivalStage III diseaseMedian radiation doseMedian treatment timeT-cell lymphomaToxicity of radiationIVB diseaseAdjuvant therapyStage IVAVisceral involvementModality therapyOverall survivalLymph nodes
1997
Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck
Haffty B, Son Y, Wilson L, Papac R, Fischer D, Rockwell S, Sartorelli A, Ross D, Sasaki C, Fischer J. Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck. International Journal Of Cancer 1997, 5: 235-245. PMID: 9372546, DOI: 10.1002/(sici)1520-6823(1997)5:5<235::aid-roi4>3.0.co;2-z.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaWhite blood cell countPhase I trialCell carcinomaRadiation therapyMitomycin CNonhematological toxicitiesI trialStage III/IV squamous cell carcinomaCourse of RTTotal median doseAcceptable toxicity profilePhase III trialsCurrent ongoing trialsDisease survival ratesDaily radiation therapyBlood cell countHypoxic cell cytotoxinActuarial survivalHemoglobin nadirsAdvanced diseaseMedian doseIII trialsOngoing trialsMultiinstitutional trial
1996
Additional courses of total skin electron beam therapy in the treatment of patients with recurrent cutaneous T-cell lymphoma
Wilson L, Quiros P, Kolenik S, Heald P, Braverman I, Edelson R, Kacinski B. Additional courses of total skin electron beam therapy in the treatment of patients with recurrent cutaneous T-cell lymphoma. Journal Of The American Academy Of Dermatology 1996, 35: 69-73. PMID: 8682967, DOI: 10.1016/s0190-9622(96)90499-5.Peer-Reviewed Original ResearchConceptsTotal skin electron beam therapyCutaneous T-cell lymphomaRecurrent cutaneous T-cell lymphomaComplete responseT-cell lymphomaElectron beam therapySecond courseMedian disease-free intervalThird courseAdditional coursesBeam therapyDisease-free intervalTreatment of patientsAcceptable risk profileForm of therapyMedian doseMedian survivalMild erythemaPatientsInitial courseTherapyVariety of modalitiesRisk profileEntire groupLocalized radiationExtent of skin involvement as a prognostic indicator of disease free and overall survival of patients with T3 cutaneous T‐cell lymphoma treated with total skin electron beam radiation therapy
Quiros P, Kacinski B, Wilson L. Extent of skin involvement as a prognostic indicator of disease free and overall survival of patients with T3 cutaneous T‐cell lymphoma treated with total skin electron beam radiation therapy. Cancer 1996, 77: 1912-1917. PMID: 8646693, DOI: 10.1002/(sici)1097-0142(19960501)77:9<1912::aid-cncr23>3.0.co;2-1.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBody Surface AreaChemotherapy, AdjuvantCohort StudiesDisease-Free SurvivalFemaleFollow-Up StudiesHumansLymphoma, T-Cell, CutaneousMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisRadiotherapy DosageRadiotherapy, High-EnergyRemission InductionRetrospective StudiesSkinSkin NeoplasmsSurvival RateConceptsTotal skin electron beam therapyCutaneous T-cell lymphomaComplete clinical responseOverall survivalSkin involvementT-cell lymphomaMedian DFSPrognostic indicatorTotal skin electron beam radiation therapyToxicity of therapyElectron beam radiation therapyBeam radiation therapyTotal skin surfaceElectron beam therapyFree survivalClinical responsePrognostic significanceTumor nodulesRadiation therapyPatientsPatient recordsTherapyDiseaseBeam therapyMonths
1994
Impact of non-CTCL dermatologic diagnoses and adjuvant therapies on cutaneous T-cell lymphoma patients treated with total skin electron beam radiation therapy
Wilson L, Cooper D, Goodrich A, Friedman N, Feldman A, Braverman I, Kacinski B. Impact of non-CTCL dermatologic diagnoses and adjuvant therapies on cutaneous T-cell lymphoma patients treated with total skin electron beam radiation therapy. International Journal Of Radiation Oncology • Biology • Physics 1994, 28: 829-837. PMID: 8138435, DOI: 10.1016/0360-3016(94)90102-3.Peer-Reviewed Original ResearchConceptsTotal skin electron beam therapySystemic adjuvant therapyRelapse-free survivalDoxorubicin/cyclophosphamide chemotherapyShorter relapse-free survivalElectron beam therapyAdjuvant therapyDermatologic diagnosesBeam therapyCyclophosphamide chemotherapyFollicular mucinosisOverall survivalT2 patientsExtracorporeal photopheresisLymphomatoid papulosisCutaneous relapseTotal skin electron beam radiation therapyCutaneous T-cell lymphoma patientsT-cell lymphoma patientsBetter relapse-free survivalClinical complete responseCohort of patientsElectron beam radiation therapyBeam radiation therapyAdjuvant chemotherapy
1993
Conservative surgery and radiation in the treatment of synchronous ipsilateral breast cancers
Wilson L, Beinfield M, McKhann C, Haffty B. Conservative surgery and radiation in the treatment of synchronous ipsilateral breast cancers. Cancer 1993, 72: 137-142. PMID: 8389664, DOI: 10.1002/1097-0142(19930701)72:1<137::aid-cncr2820720126>3.0.co;2-e.Peer-Reviewed Original ResearchConceptsIpsilateral breast cancerConservative surgeryRadiation therapyRecurrence rateBreast cancerBreast recurrence rateChest wall progressionIpsilateral breast recurrenceActuarial survival rateEvidence of diseaseLocal recurrence rateManagement of patientsSubsequent local recurrenceInvasive lobular histologyBreast recurrenceLobular histologyMedian doseMetastatic diseaseLocal recurrenceThird patientRegional lymphaticsSeparate lesionsSingle lesionSame breastPatients